Hepatitis in patients with end-stage renal disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 9-10, 1997, Pages

  Huang, Chiu Ching ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

End stage renal disease; Hepatitis; Hepatitis B; Hepatitis C; Hepatitis G

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; RIBAVIRIN;

CONFERENCE PAPER; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; PREVALENCE; PRIORITY JOURNAL; SERODIAGNOSIS;

EID: 0030835005     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00506.x     Document Type: Conference Paper

References (56)

1. Szmuness W, Prince AM, Grady GF et al. Hepatitis B infection: A point-prevalence study in 15 US hemodialysis centers. JAMA 1974; 227: 901-6.
2. Syndman DR, Bergman D, Bryan JA. Hemodialysisassociated hepatitis in United States, 1974. J. Infect. Dis. 1977; 135: 687-91.
3. Stevens CD, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. N. Engl. J. Med. 1984; 311: 496-501.
4. Harnett JD, Parfrey PS, Kennedy M, Zeldis JB, Steinmann TI, Guttmann RD. The long-term outcome of hepatitis B infection in hemodialysis patients. Am. J. Kidney Dis. 1988; 11: 210-13.
5. Degott C, Degos F, Jungers P et al. Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver 1983; 3: 377-84.
6. Harnett JD, Zeldis JB, Parfrey PS et al. Hepatitis B disease in dialysis and transplant patients: Further epidemiologic and serologic studies. Transplantation 1987; 44: 369-76.
7. Parfrey PS, Farge D, Forbes RDC, Dondavino R, Kenick S, Guttmann RD. Chronic hepatitis in end-stage renal disease: Comparison of HBsAg-negative and HBsAg-positive patients. Kidney Int. 1985; 28: 959-67.
8. Huang CC, Lai MK, Fong MT. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation 1990; 49: 540-4.
9. London WT, Drew JS, Lustbader ED, Werner BG, Blumberg BS. Host response to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int. 1977; 12: 51-8.
10. Parfrey PS, Forbes RDC, Hutchingson TA et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 1985; 39: 610-15.
11. Sengar DPS, Couture RA, Lazarovits AI, Jindal SL. Longterm patient and renal allograft survival in HBsAg infection: A recent update. Transplant. Proc. 1989; 21: 3358-9.
12. Koretz RL. Hepatitis and renal disease. In: Nissenson AR, Fine RN, Gentile DE, eds. Clinical Dialysis. Norwalk, Connecticut: Appleton & Lange, 1995; 574-606.
13. Aroldi A, Tarantino A, Montagnino G et al. Renal transplant recipients and chronic liver disease: Statistical evaluation of predisposing factors. Nephron 1992; 61: 290-2.
14. Dhar JM, Al-Khader AA, Al-Sulaiman MH, AI-Hasani MK. The significance and implications of hepatitis B infection in renal transplant recipients. Transplant. Proc. 1991; 23: 1785-6.
15. Dusheiko G, Song E, Bowyer S et al. Natural history of hepatitis B virus infection in renal transplant recipients: A fifteen year follow-up. Hepatology 1983; 3: 330-6.
16. Friedlaender MM, Tur-Kaspa R, Rubinger D, Silver J, Popovtzer MM. Renal transplantation is not contraindicated in asymptomatic carriers of hepatitis B surface antigen. Am. J. Kidney Dis. 1989; 14: 204-10.
17. Johnson DW, Fleming SJ. The use of vaccines in renal failure. Clin. Pharmacokinet. 1992; 22: 434-46.
18. Lefebure AF, Verpooten GA, Couttenye MM, De Broe ME. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine 1993; 11: 397-9.
19. Huang CC. Dialysis therapy in Taiwan: 1995 National Surveillance Report. J. Nephrol ROC 1995; 9: 71-83.
20. Huang CC, Wu MS, Lin DY, Liaw YF. The prevalence of hepatitis C virus antibodies in patients treated with continuous ambulatory peritoneal dialysis. Perit. Dial. Int. 1992; 12: 31-3.
21. Cantu P, Mangano S, Masini M, Limido A, Crovetti G, DeFilippo C. Prevalence of antibodies against hepatitis C virus in a dialysis unit. Nephron 1992; 61: 337-8.
22. Lin HH, Huang CC, Sheen IS, Lin DY, Liaw YF. Prevalence of antibodies to hepatitis C virus in hemodialysis unit. Am. J. Nephrol. 1991; 11: 192-4.
23. Huang CC, Liaw YF, Lai-MK, Chu SH, Chuang CK, Huang JY. The clinical outcome of hepatitis C virus antibody-positive renal allograft recipients. Transplantation 1992; 53: 763-5.
24. Jeffers LJ, Perez GO, De Medina MD et al. Hepatitis C infection in two urban hemodialysis units. Kidney Int. 1990; 38: 320-2.
25. Yamaguchi K, Nishimura Y, Fukuoka N et al. Hepatitis C virus antibodies in haemodialysis patients. Lancet 1990; 335: 1409-10.
26. Schlipkoter U, Roggendorf M, Ernst G et al. Hepatitis C virus antibodies in haemodialysis patients. Lancet 1990; 335: 1409.
27. Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland DV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann. Intern. Med. 1990; 112: 958-60.
28. Pol S, Romeo R, Zins B et al. Hepatitis C virus RNA in anti-HCV-positive hemodialyzed patients: Significance and therapeutic implications. In: Nishioka K, Suzuki H, Mishiro S, Ota T, eds. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994; 489-90.
29. Jadoul M. Hepatitis C virus. Lancet 1995; 345: 189-90.
30. Jadoul M. Should hemodialysis patients with hepatitis C virus antibodies be isolated? Semin. Dial. 1995; 8: 1-3.
31. Chauveau P, Bouchardeau F, Courouce AM et al. Incidence of hepatitis C infection in a dialysis centre: A five-year follow up. Nephrol. Dial. Transplant. 1994; 7: 979.
32. Martin P, Brezina M, Dixit V et al. Acquisition of hepatitis C virus by hemodialysis patients. Hepatology 1993; 18: 93A.
33. Pereira BJG, Milford EL, Kirkman RL et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N. Engl. J. Med. 1992; 327: 910-15.
34. Huang CC, Lai MK, Lin MW, Pao CC, Fang JT, Yao DS. Transmission of hepatitis C virus by renal transplantation. Transplant. Proc. 1993; 25: 1474-5.
35. Orloff SL, Stempel CA, Wright TL et al. Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clin. Transplant. 1995; 9: 119-24.
36. Ynares C, Johnson HK, Kerlin T, Crowe D, MacDonell R, Richie R. Impact of pretransplant hepatitis C antibody status upon long-term patient and renal allograft survival: A 5- and 10-year follow-up. Transplant. Proc. 1993; 25: 1466-8.
37. Roth D, Zucker K, Cirocco R et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int. 1994; 45: 238-44.
38. Ellis ME, Alfurayh O, Halim MA et al. Chronic non-A, non-B hepatitis complicated by end stage renal failure treated with recombinant Interferon alpha. J. Hepatol. 1993; 18: 210-16.
39. Raptopoulou-Gigi M, Spaia S, Garifallos A et al. Interferon-alpha-2b treatment of chronic hepatitis C in hemodialysis patients. Nephrol. Dial. Transplant. 1995; 10: 1834-7.
40. Okuda K, Hayashi H, Yokozeki K, Kondo T, Kashima T, Irie Y. Interferon treatment for chronic hepatitis C in haemodialysis patients: Suggestions based on a small series. J. Gastroenterol. Hepatol. 1995; 10: 616-20.
41. Pol S, Thiers V, Carnot F et al. Efficiency of alpha-2b Interferon in the treatment of HCV infection in hemodialyzed patients. Hepatology 1994; 20: 160A (Abstract).
42. Pol S, Thiers V, Carnot F et al. Effectiveness and tolerance of interferon-α2b in the treatment of chronic hepatitis C in haemodialysis patients. Nephrol. Dial. Transplant. 1996; 11 (Suppl. 4): 58-61.
43. Huang CC, Fan Chian CY. Inteferon alpha therapy for hemodialysis patients with chronic hepatitis C, J. Am. Soc. Nephrol. 1996; 7: 1449 (Abstract).
44. Mancini C, Gaeta A, Lorino G et al. Alpha interferon therapy in patients with hepatitis infection undergoing organ transplantation. Transplant. Proc. 1989; 21: 2429-30.
45. Chan TM, Lok ASF, Cheng IKP, Ng IOL. Chronic hepatitis C after renal transplantation: Treatment with α-interferon. Transplantation 1993; 56: 1095-8.
46. Koenig P, Vogel W, Umlauft F et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int. 1994; 45: 1507-9.
47. Bodenheimer H, Lindsay KL, Davis GL et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1994; 20: 207A.
48. Chemello L, Cavalleto L, Bernardinello E et al. Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes. In: Proceedings of the 2nd International Meeting on Hepatitis C and Related Viruses, 31 July-5 August, 1994. 1994; 204.
49. Brillanti S, Garson J, Foli M et al. A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-17.
50. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 507-12.
51. Masuko K, Mitsui T, Iwano K et al. Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N. Engl. J. Med. 1996; 334: 1485-90.
52. de Lamballerie X, Charrel RN, Dussol B. Hepatitis GB virus C in patients on hemodialysis. N. Engl. J. Med. 1996; 334: 1549.
53. Ashby M, de Medina M, Schluter V et al. Prevalence of hepatitis G virus infection in chronic hemodialysis patients. J. Am. Soc. Nephrol. 1996; 7: 1471 (Abstract).
54. de Sequera P, Cabrerizo M, Bartolome J et al. Hepatitis G virus (HGV) infection in hemodialysis patients. J. Am. Soc. Nephrol. 1996; 7: 1478 (Abstract).
55. Izopet J, Rostaing L, Sandres K et al. Impact of HGV infection in hemodialysis patients. J. Am. Soc. Nephrol. 1996; 7: 1483 (Abstract).
56. Charrel R, de Lamballerie X, Dussol B et al. Prevalence of hepatitis G virus (HGV) infection among 32 kidney transplants recipients (KTR). J. Am. Soc. Nephrol. 1996; 7: 1904 (Abstract).